Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Insmed Incorporated (NASDAQ:INSM) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Insmed Incorporated (NASDAQ:INSM) concerning whether a series of statements by Insmed Incorporated regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 8, 2016, Insmed disclosed that it had removed its European marketing application from the European Medicines Agency ("EMA") for its lung disease drug Arikayce. Insmed said its data from a mid-stage clinical study didn't support enough evidence for an approval from the EMA. The Company said it will resubmit the application when data is available from a later study.

Following this news, NASDAQ:INSM stock fell more than 18% in after-hours trading.

Based in Bridgewater, New Jersey, and founded in 1999 Insmed Incorporated focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases.

If you purchased shares of Insmed Incorporated (NASDAQ:INSM) on or before June 8, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185